BR112019012171B1 - novas formas de dosagem oral de liberação modificada e imediata de tebipenem pivoxil - Google Patents

novas formas de dosagem oral de liberação modificada e imediata de tebipenem pivoxil Download PDF

Info

Publication number
BR112019012171B1
BR112019012171B1 BR112019012171-4A BR112019012171A BR112019012171B1 BR 112019012171 B1 BR112019012171 B1 BR 112019012171B1 BR 112019012171 A BR112019012171 A BR 112019012171A BR 112019012171 B1 BR112019012171 B1 BR 112019012171B1
Authority
BR
Brazil
Prior art keywords
dosage form
tebipenem
release
tebipenem pivoxil
pivoxil
Prior art date
Application number
BR112019012171-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112019012171A2 (pt
Inventor
Jain Akash
Lu Enxian
Lyu Shaoqiong
Li Shoufeng
Keutzer Timothy
Utley Luke
Fraczkiewicz Grazyna
Macwan Joyce
Original Assignee
Spero Therapeutics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spero Therapeutics, Inc filed Critical Spero Therapeutics, Inc
Publication of BR112019012171A2 publication Critical patent/BR112019012171A2/pt
Publication of BR112019012171B1 publication Critical patent/BR112019012171B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112019012171-4A 2016-12-15 2017-12-15 novas formas de dosagem oral de liberação modificada e imediata de tebipenem pivoxil BR112019012171B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662434643P 2016-12-15 2016-12-15
US62/434,643 2016-12-15
US201662438071P 2016-12-22 2016-12-22
US62/438,071 2016-12-22
PCT/US2017/066729 WO2018112372A1 (en) 2016-12-15 2017-12-15 Novel tebipenem pivoxil immediate and modified release oral dosage forms

Publications (2)

Publication Number Publication Date
BR112019012171A2 BR112019012171A2 (pt) 2019-12-17
BR112019012171B1 true BR112019012171B1 (pt) 2021-02-09

Family

ID=60937949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012171-4A BR112019012171B1 (pt) 2016-12-15 2017-12-15 novas formas de dosagem oral de liberação modificada e imediata de tebipenem pivoxil

Country Status (15)

Country Link
US (2) US12226403B2 (https=)
EP (2) EP3554484B1 (https=)
JP (2) JP7083828B2 (https=)
KR (1) KR102640532B1 (https=)
CN (2) CN110072520A (https=)
AU (2) AU2017377062B2 (https=)
BR (1) BR112019012171B1 (https=)
CA (1) CA3045566C (https=)
CO (1) CO2019006183A2 (https=)
ES (1) ES3037252T3 (https=)
IL (1) IL267219B2 (https=)
MX (3) MX2019007136A (https=)
PH (1) PH12019501234A1 (https=)
WO (1) WO2018112372A1 (https=)
ZA (1) ZA201903309B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072520A (zh) 2016-12-15 2019-07-30 斯派尔治疗有限公司 新型替比培南匹伏酯速释和调释口服剂型
NZ753781A (en) * 2017-02-06 2022-10-28 Spero Therapeutics Inc Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
CN109432044B (zh) * 2018-11-27 2021-05-11 山东省药学科学院 一种替比培南酯细粒剂及其制备方法
EP4243783A1 (en) * 2020-11-11 2023-09-20 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation
CN115969815A (zh) * 2023-02-10 2023-04-18 鲁南贝特制药有限公司 一种替比培南酯口服制剂及其制备方法
CN118526466B (zh) * 2024-07-22 2024-11-05 山东则正医药技术有限公司 一种替比培南匹伏酯颗粒制剂及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
AU682510B2 (en) 1993-07-01 1997-10-09 Pfizer Japan Inc. 2-(1-(1,3-thiazolin-2-yl)azetidin-3-yl)thio-carbapenem derivatives
JP3317604B2 (ja) 1994-12-28 2002-08-26 日本ワイスレダリー株式会社 結晶形態のカルバペネム化合物
TW420681B (en) 1995-12-08 2001-02-01 Lederle Japan Ltd Carbapenem-3-carboxylic acid ester derivatives
JP2847093B2 (ja) 1996-03-11 1999-01-13 ソニー株式会社 ビデオカメラ
JP3317649B2 (ja) 1997-01-13 2002-08-26 日本ワイスレダリー株式会社 結晶形態のカルバペネム化合物
JP2003171277A (ja) 2001-12-07 2003-06-17 Wyeth Lederle Japan Ltd 薬物放出時間制御型固形製剤
CA2476201C (en) * 2002-02-21 2009-09-01 Biovail Laboratories Incorporated Modified release formulations of at least one form of tramadol
JP2004035517A (ja) * 2002-07-08 2004-02-05 Wyeth Lederle Japan Ltd カルバペネム系抗生剤含有経口製剤
JP2004035518A (ja) 2002-07-08 2004-02-05 Wyeth Lederle Japan Ltd 苦味をマスキングしたカルバペネム系抗生剤含有経口顆粒製剤
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US20080069879A1 (en) 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
CN101868460A (zh) * 2007-11-23 2010-10-20 国际药品工业株式会社 2-芳基甲基吖丁啶-碳青霉烯-3-羧酸酯衍生物或其盐、其制备方法以及包含上述的药物组合物
KR100950699B1 (ko) 2008-03-28 2010-03-31 국제약품공업주식회사 2-아릴메틸아제티딘-카바페넴-3-카복실산 에스테르유도체의 산부가염, 이의 제조방법 및 이를 포함하는 약학조성물
CN102558181B (zh) 2010-12-15 2015-04-22 石药集团中奇制药技术（石家庄）有限公司 一种碳青霉烯抗生素的制备方法
CN102731507B (zh) 2011-04-13 2015-04-01 石药集团中奇制药技术（石家庄）有限公司 泰比培南晶型、其制备方法及其在制备药物中的应用
CN102276611B (zh) 2011-05-18 2013-01-09 深圳万乐药业有限公司 一种替比培南酯的重结晶精制方法
CN102860985B (zh) * 2011-07-06 2015-02-25 石药集团中奇制药技术（石家庄）有限公司 一种泰比培南酯口服制剂及其制备方法
CN103371977A (zh) * 2012-04-25 2013-10-30 秦引林 一种泰比培南酯颗粒及其制备方法
CN102885811B (zh) 2012-08-27 2014-05-28 南京华威医药科技开发有限公司 含有泰比培南酯的口服制剂
CN103664948B (zh) 2012-09-05 2015-12-16 凌沛学 一种替比培南酯的中间体的结晶及其制备方法
CN103664949A (zh) 2012-09-12 2014-03-26 高瑞耀业(北京)科技有限公司 替比培南匹伏酯结晶及其制备方法
CN102836130A (zh) 2012-09-19 2012-12-26 山东罗欣药业股份有限公司 一种替比培南匹伏酯颗粒剂
CN103655483A (zh) 2012-09-26 2014-03-26 扬州市星斗药业有限公司 一种含有替比培南的颗粒及其制备方法
CN103054815B (zh) * 2013-02-04 2015-12-02 南京卡文迪许生物工程技术有限公司 替比培南酯口服固体制剂及其制备方法
CN104224725A (zh) 2013-06-14 2014-12-24 北京济美堂医药研究有限公司 一种替比培南酯颗粒剂及其制备方法
CN104027310B (zh) 2013-12-26 2016-02-03 青岛大学 一种法罗培南钠颗粒剂及其制备方法
CN104013583B (zh) * 2014-06-27 2019-02-26 国药集团致君（深圳）制药有限公司 一种泰比培南酯组合物的药物制剂及其制备方法
CN105193742A (zh) 2015-10-30 2015-12-30 海口市制药厂有限公司 替比培南酯颗粒剂组合物、其制备方法及应用
CN105997891A (zh) * 2016-05-20 2016-10-12 郑州明泽医药科技有限公司 一种替比培南酯制剂及其制备方法
CN105963261A (zh) 2016-07-08 2016-09-28 河南全宇制药股份有限公司 一种替比培南酯颗粒剂及其制备方法
CN110072520A (zh) 2016-12-15 2019-07-30 斯派尔治疗有限公司 新型替比培南匹伏酯速释和调释口服剂型
NZ753781A (en) 2017-02-06 2022-10-28 Spero Therapeutics Inc Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
CN107737107B (zh) 2017-12-02 2020-05-29 北京达因高科儿童药物研究院有限公司 一种含替比培南酯组合物的口服制剂及其制备方法
EP4243783A1 (en) 2020-11-11 2023-09-20 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation

Also Published As

Publication number Publication date
CO2019006183A2 (es) 2019-08-30
ES3037252T3 (en) 2025-09-30
NZ753713A (en) 2021-09-24
JP7083828B2 (ja) 2022-06-13
MX2022006971A (es) 2022-07-13
KR102640532B1 (ko) 2024-02-26
ZA201903309B (en) 2020-09-30
US20250009718A1 (en) 2025-01-09
AU2017377062B2 (en) 2020-09-03
US12226403B2 (en) 2025-02-18
AU2020281095A1 (en) 2021-01-07
CA3045566A1 (en) 2018-06-21
BR112019012171A2 (pt) 2019-12-17
IL267219A (en) 2019-08-29
MX2022014095A (es) 2022-12-08
CA3045566C (en) 2024-04-09
EP3554484B1 (en) 2025-05-14
EP4032531A1 (en) 2022-07-27
US20200016126A1 (en) 2020-01-16
AU2020281095B2 (en) 2022-10-06
JP2022116261A (ja) 2022-08-09
IL267219B1 (en) 2024-09-01
MX2019007136A (es) 2019-09-27
PH12019501234A1 (en) 2019-10-07
KR20190097109A (ko) 2019-08-20
WO2018112372A1 (en) 2018-06-21
EP3554484A1 (en) 2019-10-23
CN110072520A (zh) 2019-07-30
AU2017377062A1 (en) 2019-06-06
JP7431886B2 (ja) 2024-02-15
JP2020511419A (ja) 2020-04-16
CN115192533A (zh) 2022-10-18
IL267219B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP7431886B2 (ja) 新規テビペネムピボキシルの即放性および調節放出性経口剤形
BR112012021275B1 (pt) Formulação compreendendo um adsorvente misturado com carragenina, para entrega oral e liberação controlada de adsorventes no intestino, e, uso de uma formulação
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
HK40081204A (en) Novel tebipenem pivoxil hbr tablet
NZ753713B2 (en) Novel tebipenem pivoxil immediate and modified release oral dosage forms
EA044993B1 (ru) Лекарственная форма с немедленным высвобождением для перорального применения, содержащая тебипенем пивоксил
TWI743059B (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
BRPI1007346B1 (pt) Composição farmacêutica cronoterapêutica
JP2017081950A (ja) 薬学的組成物

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2017, OBSERVADAS AS CONDICOES LEGAIS.